West Pharmaceutical Services Inc.: Q3 FY2026 earnings call

What management said about Q3 FY2026, from the documents filed with the SEC on 29 October 2026: press release. Guidance figures: 4 raised, 1 lowered. The quarter’s numbers.

Read the filing

Key takeaways

• Net sales grew 8.7%, organic 11.9%: Net sales were $874.5 million, up 8.7% from $804.6 million a year earlier. Organic growth was 11.9% after excluding foreign exchange and the SmartDose 3.5mL transaction. Source
• Diluted and adjusted EPS both rose: Diluted EPS was $3.02, up 57.3% from $1.92. Adjusted-diluted EPS was $2.66, up 35.7%, after excluding unallocated items such as the SmartDose gain. Source
• Full-year sales and EPS guidance raised: Management raised full-year net sales and adjusted-diluted EPS guidance and lowered capital spending guidance, as detailed in the guidance section. Source
• HVP Components grew 19.7%: HVP Components net sales were $466.7 million, up 19.7% reported and 20.3% organic. HVP Components accounted for 53% of total company net sales in the quarter. Source
• Gross profit margin rose to 39.7%: Gross profit margin was 39.7% for the quarter, against 36.6% a year earlier. Nine-month gross margin was 37.5%, against 35.3%. Source
• SmartDose 3.5mL gain recorded: The net gain on the SmartDose 3.5mL asset sale was $55.7 million, recorded in other expense (income) in the quarter and nine months. Unallocated M&A items were a net benefit of $54.0 million for the quarter. Source
• Buybacks of $231 million in quarter: The company repurchased $231 million of stock in the quarter. Year-to-date repurchases reached $685 million, against $134.0 million in the first nine months of 2025. Source

“Our results were again led by our High-Value Product (HVP) Components business.”

Michel Lagarde, President and Chief Executive Officer

Guidance

What changed from last quarter

• Guidance raised: Full-year net sales guidance raised to $3.41 billion to $3.42 billion from $3.345 billion to $3.380 billion. Source
• Guidance raised: Organic net sales growth guidance raised to 11.3% to 11.6% from 10% to 11%. Source
• Guidance raised: Adjusted-diluted EPS guidance raised to $9.38 to $9.48 from $8.85 to $9.05. Source
• Guidance lowered: Capital spending guidance lowered to $215 million to $220 million from $250 million to $275 million. Source
• Ended: SmartDose 3.5mL product sales are not expected to continue; the release expects no further sales for the rest of 2026. Source
• New: The October release names Michel Lagarde as President and Chief Executive Officer; the July release named Eric M. Green in that role. Source

Third-quarter results and guidance

• Net sales grew 8.7%, organic 11.9%: Net sales were $874.5 million, up 8.7% from $804.6 million a year earlier. Organic growth was 11.9% after excluding foreign exchange and the SmartDose 3.5mL transaction. Source
• Diluted and adjusted EPS both rose: Diluted EPS was $3.02, up 57.3% from $1.92. Adjusted-diluted EPS was $2.66, up 35.7%, after excluding unallocated items such as the SmartDose gain. Source
• Operating profit rose sharply: Reported operating profit was $267.4 million, a 30.6% margin, against $167.6 million and 20.8% a year earlier. Adjusted operating profit was $221.5 million. Source
• Full-year sales and EPS guidance raised: Management raised full-year net sales and adjusted-diluted EPS guidance and lowered capital spending guidance, as detailed in the guidance section. Source

Segments and regions

• Proprietary Products grew 12.6%: Proprietary Products net sales were $728.8 million, up 12.6% reported and 16.6% organic. The segment was 83% of total net sales in the quarter. Source
• West Vantage sales declined 7.3%: West Vantage net sales were $145.7 million, down 7.3% reported and 6.6% organic, representing 17% of total company net sales. Source
• Regional growth led by Asia Pacific: Americas sales were $401.3 million, up 6.9% (organic 12.4%). EMEA sales were $376.1 million, up 4.2% (organic 5.7%). Asia Pacific sales were $97.1 million, up 42.4% (organic 41.9%). Source

“We are grateful for the trust our customers put in us, and we remain committed to driving continuous improvement to even better serve their current and future needs.”

Michel Lagarde, President and Chief Executive Officer

Products and market groups

• HVP Components grew 19.7%: HVP Components net sales were $466.7 million, up 19.7% reported and 20.3% organic. HVP Components accounted for 53% of total company net sales in the quarter. Source
• Delivery Devices flat reported, up organically: HVP Delivery Devices sales were $99.1 million, flat reported. Excluding FX and the SmartDose 3.5mL divestiture, sales grew 26.4%; SmartDose 3.5mL sales were $11.8 million against $29.8 million. Source
• Standard Products rose 2.9%: Standard Products net sales were $163.0 million, up 2.9% reported and 3.1% organic, accounting for 19% of total company net sales. Source
• Biologics up, Generics down: Biologics net sales were $379.3 million, up 15.3% (organic 23.2%). Generics fell 5.7% to $128.2 million (organic down 4.5%). Pharma rose 21.3% to $221.3 million. Source

Margins and costs

• Gross profit margin rose to 39.7%: Gross profit margin was 39.7% for the quarter, against 36.6% a year earlier. Nine-month gross margin was 37.5%, against 35.3%. Source
• West Vantage gross profit fell: West Vantage gross profit was $24.0 million, against $30.3 million a year earlier. Proprietary Products gross profit was $323.4 million, against $264.0 million. Source
• SG&A expense increased: Selling, general and administrative expenses were $112.9 million, up from $102.7 million, and stayed at 13% of net sales. Research and development was $18.3 million, against $17.1 million. Source
• Other income reflects SmartDose gain: Other expense (income), net was $51.2 million of income, against $6.9 million of expense a year earlier. The line includes the SmartDose 3.5mL gain described below. Source
• Income tax expense rose: Income tax expense was $58.0 million for the quarter, against $34.0 million. For the nine months it was $134.9 million, against $88.3 million. Source

SmartDose sale and one-time items

• SmartDose 3.5mL gain recorded: The net gain on the SmartDose 3.5mL asset sale was $55.7 million, recorded in other expense (income) in the quarter and nine months. Unallocated M&A items were a net benefit of $54.0 million for the quarter. Source
• One-time tax cost on SmartDose gain: The company recorded a one-time tax cost of $22.4 million tied to the SmartDose gain. Separately, a $12.0 million one-time tax cost from an internal legal entity restructuring was recorded in the first quarter. Source
• Unallocated items lift reported profit: Unallocated items were $(45.9) million in the quarter, removing net gains from reported operating profit. Adjusted operating profit was $221.5 million, a 25.3% margin, against 21.1% a year earlier. Source

Capital, cash and shareholder returns

• Buybacks of $231 million in quarter: The company repurchased $231 million of stock in the quarter. Year-to-date repurchases reached $685 million, against $134.0 million in the first nine months of 2025. Source
• Dividend raised 18% to $0.26: The Board declared a fourth-quarter dividend of $0.26 per share, up 18% from $0.22 per share paid in the prior quarter. The declaration was announced October 19, 2026. Source
• Operating cash flow and capital spending: Nine-month operating cash flow was $403.4 million, against $503.7 million. Nine-month capital expenditures were $125.0 million, against $209.8 million. Source
• Working capital absorbed cash: Changes in assets and liabilities used $208.2 million in the nine months, against $1.9 million a year earlier. Cash and equivalents were $464.1 million, against $791.3 million at December 31, 2025. Source
• Average diluted share count lower: Average diluted shares were 70.8 million in the quarter, against 72.6 million a year earlier, as repurchases reduced the share count. Source

Leadership and company profile

• New President and CEO named: The October release names Michel Lagarde as President and Chief Executive Officer. The July release named Eric M. Green as President, Chief Executive Officer and Chair of the Board. Source
• Prior release named Green: The July release named Eric M. Green as President, Chief Executive Officer and Chair of the Board. The October release does not name him.
• West as containment and delivery partner: The release describes West as a primary containment and drug delivery partner for pharmaceutical companies, biotechs and CDMOs around the world. Source

Figures management reported

Risks management discussed

• Operational: Nonrecurring professional fees for certain legal matters and the May 2026 cybersecurity incident are recorded in SG&A and excluded from adjusted results. Source

Earlier plans management reported on

• Ahead: July guidance set Q3 net sales at $820 million to $835 million and adjusted EPS at $2.14 to $2.24. Reported Q3 net sales were $874.5 million and adjusted EPS was $2.66. Source
• Not stated: The release refers to the agreement to sell SmartDose 3.5mL and associated facilities to AbbVie. The nine-month cash flow shows $126.9 million of proceeds from sale of assets. Source

Other quarters

• Q2 FY2026 earnings call
• Q1 FY2026 earnings call
• Q4 FY2025 earnings call
• Q3 FY2025 results

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.